DiaMedica Therapeutics (NASDAQ:DMAC) Announces Earnings Results

DiaMedica Therapeutics (NASDAQ:DMAC) posted its quarterly earnings data on Monday. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01, FiscalAI reports.

DiaMedica Therapeutics Trading Down 1.5%

DMAC traded down $0.10 on Monday, hitting $6.65. 180,586 shares of the company’s stock traded hands, compared to its average volume of 204,830. The company’s 50 day simple moving average is $6.60 and its 200-day simple moving average is $6.95. DiaMedica Therapeutics has a one year low of $4.39 and a one year high of $10.42. The firm has a market cap of $358.30 million, a price-to-earnings ratio of -9.37 and a beta of 1.01.

Analysts Set New Price Targets

A number of research firms have commented on DMAC. Weiss Ratings restated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. Wall Street Zen raised shares of DiaMedica Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 6th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Institutional Investors Weigh In On DiaMedica Therapeutics

A number of institutional investors have recently added to or reduced their stakes in DMAC. Jump Financial LLC purchased a new position in shares of DiaMedica Therapeutics in the fourth quarter worth $89,000. Truvestments Capital LLC grew its stake in DiaMedica Therapeutics by 112.3% during the fourth quarter. Truvestments Capital LLC now owns 9,849 shares of the company’s stock valued at $78,000 after acquiring an additional 5,210 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in DiaMedica Therapeutics in the 4th quarter valued at $89,000. Intech Investment Management LLC lifted its stake in DiaMedica Therapeutics by 32.5% in the 4th quarter. Intech Investment Management LLC now owns 18,460 shares of the company’s stock worth $147,000 after purchasing an additional 4,525 shares in the last quarter. Finally, Bank of America Corp DE lifted its stake in DiaMedica Therapeutics by 44.2% in the 3rd quarter. Bank of America Corp DE now owns 12,249 shares of the company’s stock worth $84,000 after purchasing an additional 3,752 shares in the last quarter. 10.12% of the stock is owned by hedge funds and other institutional investors.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical‐stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein‐kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.